Biosimilar and Biopharmaceutical Production

Iran's pharmaceutical industry produces over 95% of domestic medicine demand, a level of self-sufficiency achieved through decades of deliberate import substitution accelerated by sanctions. The industry's most advanced segment is biosimilar production — manufacturing near-identical copies of complex biological drugs including monoclonal antibodies (rituximab, trastuzumab, bevacizumab), interferons, erythropoietin, and insulin. Approximately 60 Iranian companies produce biopharmaceuticals, with the domestic pharmaceutical market valued at approximately $7.9 billion.

Biosimilars are among the most technically demanding pharmaceutical products to manufacture, requiring cell culture systems, complex purification processes, and analytical characterization capabilities. Iran's ability to produce these products domestically — even if quality systems may not uniformly meet EMA/FDA standards — represents genuine biotechnology manufacturing capability. The industry has expanded from simple generic drug formulation to complex biologics over roughly three decades, driven by the existential need to provide medicines to a population of 88 million.

The pharmaceutical self-sufficiency model has strategic dimensions beyond healthcare. In conflict scenarios, sanctions tightening, or supply chain disruptions, Iran's ability to produce essential medicines domestically provides a form of biological security. The sector also represents an export opportunity — Iran supplies pharmaceuticals to Iraq, Afghanistan, and other neighboring markets. The challenge is quality harmonization: accessing regulated markets in Europe or North America would require compliance with stringent Good Manufacturing Practice standards that many Iranian facilities have not yet achieved.